Two new studies examining prevention strategies for respiratory syncytial virus (RSV) suggest that both maternal vaccination ...

Infants given the monoclonal antibody nirsevimab (Beyfortus) to provide passive immunity against respiratory syncytial virus ...

Local reporting and CDC maps indicate that flu and RSV infections are rising in Georgia, with doctors observing an uptick in ...

Nirsevimab, a long-acting monoclonal antibody that confers passive immunity for infants up to 6 months old, was approved in ...

France: Researchers have found in a new study that passive infant immunization with nirsevimab was associated with lower ...

The recent safety review of two approved RSV preventive treatments for infants initiated by the U.S. Food and Drug Administration is unusual and could have unintended consequences for public trust and ...

(Reuters) -Infant hospitalizations due to respiratory syncytial virus (RSV) infections in the United States dropped as much as 43% last year compared to previous years, following the widespread ...

The study included 31,900 infants, 49.1% of whom received nirsevimab. HealthDay News — Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower ...

RSV can feel like a simple cold, but for some, it can lead to serious illness. Learn how you can help protect you and your ...

Peak season ranges from late December to mid-February every year, the CDC website says. Last year in North Carolina, RSV ...

A 4-month-old baby from Acworth is in intensive care with flu, RSV, and pneumonia as Georgia sees a sharp rise in respiratory ...